Health care stocks were declining pre-bell Monday, with the Health Care Select Sector SPDR Fund (XLV) 0.3% lower and the iShares Biotechnology ETF (IBB) down 0.6%.

Belite Bio (BLTE) shares were up more than 11% after the company said a phase 3 trial of Tinlarebant to treat Stargardt disease type 1 met its primary efficacy endpoint.

Kestra Medical Technologies (KMTS) stock was down more than 3% after the company reported a wider preliminary fiscal Q2 operating loss.

IDEAYA Biosciences (IDYA) shares were up more than 5% after the company said it has received clearance from the US Food and Drug Administration for an investigational new drug application to begin a Phase 1 trial of IDE034.